



FDA ADVISORY  
No. 2020-816-A

25 NOV 2020

TO: **THE GENERAL PUBLIC**

SUBJECT: **Lifting the Advisory of the Registered Food Product PARAGIS CAFÉ LATTE Coffee Mix with Folic Acid under FDA Advisory No. 2020-816 with the Subject "Public Health Warning Against the Purchase and Consumption of the Unregistered Food Supplements"**

The Food and Drug Administration (FDA) informs the public that the food product **PARAGIS CAFÉ LATTE Coffee Mix with Folic Acid** is now registered by the Market Authorization Holder, **Premium Herbs Corp.** in accordance to existing FDA rules and regulations.



Figure 1. Approved Primary and Secondary labels of **PARAGIS CAFÉ LATTE Coffee Mix with Folic Acid** with registration number **FR-4000007003752** valid until 21 October 2024.

Accordingly, the list released in FDA Advisory No. 2020-816 is hereby updated to remove the aforementioned food product.




The public is advised to always check if a food product or food supplement is registered with the FDA. The FDA website ([www.fda.gov.ph](http://www.fda.gov.ph)) has a Search feature which may be used by typing in the name of the product before purchasing. Kindly contact the FDA Center for Food Regulation and Research through e-mail at [cfrr@fda.gov.ph](mailto:cfrr@fda.gov.ph), or call (02) 8857-1900 loc. 8112 or 8105.

To report any sale or distribution of unregistered food products, the online reporting facility, **eReport** can be accessed at [www.fda.gov.ph/ereport](http://www.fda.gov.ph/ereport).

The public health warning imposed on the remaining product listed in FDA Advisory No. 2020-816, shall remain to be upheld and shall not be affected by the issuance of this advisory. Furthermore, the issuance of this advisory shall not in any manner preclude this Office from issuing subsequent orders it may deem necessary and appropriate, should there be findings of any violation of the company to the existing laws, rules, and regulations.

Dissemination of this advisory to all concerned is hereby requested.

  
**ROLANDO ENRIQUE D. DOMINGO, MD**  
Director General